Short answer
Alamar Biosciences Inc (ALMR) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026.
Alamar Biosciences Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Press release Exhibit 99.1 contains the company’s reported financial results
Item 5.02 · Departure/Election of Directors or Officers
- President Timothy “Tod” White retiring effective December 31, 2026 after more than five years
- Six-month consulting arrangement through June 30, 2027 supports leadership transition and operational continuity
- CEO and founder Yuling Luo becomes the key continuing executive during the company’s next growth phase
- Departure follows multiple fundraising rounds and foundation-building, making successor execution important for investors
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $33.5M, up 68% year over year, led by consumables growth of 79% to $17.8M
- Gross margin improved to 61.5% from 59.7%, but operating expenses rose 81% to $35.8M
- Operating loss widened to $15.1M and net loss to $13.3M, including $3.9M of stock-based compensation
- 2026 revenue guidance raised to $121M-$123M from $116M-$120M, implying 64% midpoint growth
- UK Biobank and GSK collaborations expand validation and potential demand for NULISA in large-scale research programs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alamar Biosciences Inc 8-K filings
Get the next ALMR 8-K as it lands
Follow ALMR for push alerts, or ask the research agent what this filing means.